8-K: Intellia Therapeutics Opts Out of Factor IX Co-Development Agreement with Regeneron

Intellia Therapeutics has terminated its co-development agreement with Regeneron for Factor IX gene editing products, shifting to a licensing agreement for future development.

Summary

• Intellia Therapeutics has notified Regeneron of its decision to terminate the Factor IX Co-Development and Co-Funding Agreement, effective 180 days after the notice date of March 19, 2024.
• The termination means Intellia will no longer share 35% of development costs or receive 35% of profits for Factor IX gene editing products.
• Future development of Factor IX products will be governed by the existing License and Collaboration Agreement (LCA) between the two companies.
• Under the LCA, Intellia could receive up to $320 million in milestone payments and royalties ranging from high-single digits to low teens, subject to potential reductions and offsets.
• The termination does not affect other collaborations between Intellia and Regeneron.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the co-development agreement is terminated, the company retains potential for significant milestone payments and royalties. The shift to a licensing agreement is a strategic decision, not necessarily a negative development.

Positives

• Intellia retains the potential to receive up to $320 million in milestone payments and royalties under the LCA.
• The termination simplifies the financial obligations for Intellia regarding Factor IX development.
• The existing License and Collaboration Agreement (LCA) provides a framework for future collaboration with Regeneron on Factor IX products.

Negatives

• Intellia will no longer receive 35% of the profits from Factor IX gene editing products.
• Intellia will no longer share 35% of the development costs for Factor IX gene editing products.
• The royalties under the LCA are subject to potential reductions, offsets, and upstream payment obligations.

Risks

• The termination of the Co-Co Agreement could impact the pace of development for Factor IX gene editing products.
• There are risks related to Intellia's ability to protect and maintain its intellectual property position.
• The success of the collaboration with Regeneron is subject to risks related to the development and commercialization of product candidates.
• The actual milestone payments and royalties received by Intellia may differ from the potential $320 million due to various factors.

Future Outlook

The future development of Factor IX gene editing products will be governed by the License and Collaboration Agreement (LCA) between Intellia and Regeneron, with Intellia potentially receiving milestone payments and royalties.

Management Comments

• Intellia notified Regeneron that the Company is opting out of its Factor IX Co-Development and Co-Funding Agreement.

Industry Context

This announcement reflects a shift in the collaboration strategy between Intellia and Regeneron, moving from a co-development model to a licensing agreement for Factor IX gene editing products. This is not uncommon in the biotech industry as companies refine their focus and financial commitments.

Comparison to Industry Standards

• Co-development agreements are common in the biotech industry, but companies often adjust these agreements based on strategic priorities and financial considerations.
• Licensing agreements, like the LCA, are a standard way for companies to monetize their intellectual property and participate in the success of products developed by other companies.
• The potential for $320 million in milestone payments is significant, but the actual amount received will depend on the success of the Factor IX program.
• Royalties in the high-single digits to low teens are within the typical range for biotech licensing agreements, but the specific terms and conditions can vary widely.

Stakeholder Impact

• Shareholders may react to the change in the collaboration agreement, but the potential for milestone payments and royalties could be viewed positively.
• Employees involved in the Factor IX program may experience changes in their roles and responsibilities.
• Regeneron will continue to develop Factor IX products under the LCA.

Next Steps

• The Co-Co Agreement will terminate 180 days after March 19, 2024.
• Intellia will continue to support Regeneron with the development of gene editing products directed to factor IX under the LCA.

Key Dates

Keywords

Intellia Therapeutics, Regeneron Pharmaceuticals, Factor IX, Gene Editing, Co-Development Agreement, License Agreement, Milestone Payments, Royalties, Collaboration, Termination